Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Histopathological Examination of Iris Tissue in Buphthalmos

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04011878
Recruitment Status : Completed
First Posted : July 9, 2019
Last Update Posted : July 9, 2019
Sponsor:
Information provided by (Responsible Party):
Hassan Lotfy Fahmy, Assiut University

Brief Summary:
To revise the etiology of the primary congenital glaucoma in some infants.

Condition or disease Intervention/treatment Phase
Iris Disease Procedure: Combined trabeculotomy trabeculectomy with mitomycin C Not Applicable

Detailed Description:
Combined trabeculotomy trabeculectomy with mitomycin C was done in 11 eyes. Histopathological examination of the peripheral iris tissue specimen was done in all cases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Histopathological Examination of Iris Tissue in Buphthalmos
Actual Study Start Date : January 2016
Actual Primary Completion Date : October 2018
Actual Study Completion Date : October 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: isolated trabeculodysgensis
etiology of primary congenital glaucoma
Procedure: Combined trabeculotomy trabeculectomy with mitomycin C
Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases




Primary Outcome Measures :
  1. fibrovascular membrane over iris surface [ Time Frame: 6 month ]
    angle closure by a fibrovascular tissue proliferation over the trabecular meshwork in the anterior chamber angle.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • infants under age of 2 years
  • 1ery glaucoma

Exclusion Criteria:

  • infants more than 2 years
  • 2ery glaucoma
  • previous glaucoma surgery
Layout table for additonal information
Responsible Party: Hassan Lotfy Fahmy, Prof., Assiut University
ClinicalTrials.gov Identifier: NCT04011878    
Other Study ID Numbers: 2323299
First Posted: July 9, 2019    Key Record Dates
Last Update Posted: July 9, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hydrophthalmos
Iris Diseases
Eye Abnormalities
Eye Diseases
Glaucoma, Open-Angle
Glaucoma
Ocular Hypertension
Congenital Abnormalities
Infant, Newborn, Diseases
Uveal Diseases
Mitomycins
Mitomycin
Antibiotics, Antineoplastic
Antineoplastic Agents
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors